The Israel Securities Authority Approval for the updating of The Tel-Aviv Stock Exchange custody fee
The Israel Securities Authority Approval for the updating of The Tel-Aviv Stock Exchange custody fee
PR Newswire
TEL AVIV, Israel, Sept. 25, 2024
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Further to the report dated July 18, 2024 (reference no.: 2024-01- 076141) ("the Report"), The Tel-Aviv Stock Exchange Ltd. ("TASE") (TASE:TASE) hereby announces that, on Sep 25, 2024, an approval was received from the Israel Securities Authority for the updating of the custody fee (account management fees) that the TASE Clearing House charges from Clearing House members that are not exclusively custodians, following the approval of said update by the Board of Directors of TASE. Upon receiving the approval of the Israel Securities Authority, the custody fee (account management fees) shall be updated in three annual steps: the first step will commence on 1.1.2025, the second at the end of a year of said date, and the third at the end of two years of said date.
For additional information, find the Report>
Contact:
Orna Goren
Head of Communication and Public Relations Unit
Tel: +972 76 8160405
tase.ir@tase.co.il
View original content:https://www.prnewswire.com/news-releases/the-israel-securities-authority-approval-for-the-updating-of-the-tel-aviv-stock-exchange-custody-fee-302258994.html
SOURCE The Tel Aviv Stock Exchange Ltd.
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks